NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » pressreleases » Thermo Fisher Scientific to Showcase New Innovative Laboratory Solutions at AMP 2022


Thermo Fisher Scientific to Showcase New Innovative Laboratory Solutions at AMP 2022

CARLSBAD, Calif.–(BUSINESS WIRE)– Thermo Fisher Scientific, the world leader in serving science, is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology (AMP) taking place at the Phoenix Convention Center from Nov. 1-5. The solutions on display are designed to address a broad range of disease states and include assays and instruments that leverage real-time and digital PCR, as well as next generation sequencing (NGS) platforms.

“Diagnostic tools and access to the most advanced platforms are critical pieces of an effective health care infrastructure because they help clinical laboratories successfully address the challenges they face in assessing health,” said Mark Smedley, Senior Vice President and President, Genetic Sciences Group of Thermo Fisher Scientific. “We are committed to continually developing both research and diagnostic innovative solutions to drive toward bettering human health, and we look forward to sharing our latest molecular diagnostic tools that support this endeavor.”

Genetic Testing Solutions

As laboratories continue to seek ways to leverage their increased testing capacity following the peak of the COVID-19 pandemic, Thermo Fisher has developed new solutions for other disease research areas, such as respiratory illness, gastrointestinal and urinary tract infections, sexually transmitted diseases, HIV drug resistance, and pharmacogenomics. Some of the research products highlighted at AMP include:

  • An update to its infectious disease testing portfolio, which now includes the Applied Biosystems TrueMark Respiratory Panels for viral, bacterial and syndromic testing for research.
  • The Applied Biosystems QuantStudio Absolute Q Digital PCR System – a plate-based digital PCR (dPCR) research platform powered by proprietary microfluidic array plate (MAP) technology that enables all necessary steps for dPCR—compartmentalizing, thermal cycling and data acquisition—to be conducted on a single instrument.
  • Thermo Fisher’s newly expanded Absolute Q Liquid Biopsy dPCR Assays include products that enable reproducible, specific detection of known somatic mutations for cancer research. Each predesigned assay has been validated using controls to detect down to 0.1% variant allele frequency and can provide results to researchers in less than two hours.
  • The Applied Biosystems Absolute Q SARS-CoV-2 Wastewater Surveillance Kit, designed to provide simple, rapid, and consistent absolute quantitation of relevant SARS-CoV-2 targets from wastewater samples by dPCR.
  • The Applied Biosystems HIV-1 Genotyping Kit with Integrase, which examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretroviral therapeutics.


Some of the diagnostic products highlighted at AMP include:


Next Generation Sequencing

To support laboratory needs for fast, comprehensive genomic profiling (CGP), Thermo Fisher is introducing the Genomic Instability Metric (GIM) as an approach to measure genomic scarring related to homologous recombination deficiency (HRD). Details will be presented during one of several company-sponsored workshops at AMP. Thermo Fisher will also feature the Ion Torrent Genexus System, a true end-to-end NGS workflow designed to provide genomic profiling results in as little as one day.

The company’s booth will also feature the Thermo Scientific AcroMetrix Oncology Hotspot Control, a highly multiplexed quality control solution that can help assess the performance of NGS assays that detect somatic mutations. It is also intended to provide a means for assessing day-to-day test variation and can help identify increases in random or systematic error.

Thermo Fisher is launching the Molecular Diagnostics Assay Developer Program for OEM partners. This free plan helps companies pursue the development of assays using PCR products, isothermal amplification and NGS workflows. The program also provides access to discounts and commercial rights as companies develop molecular tests.

Workshops and Posters

Thermo Fisher is sponsoring eleven workshops, many of which will highlight the company’s latest platforms and assays, and 19 posters with topics ranging from infectious disease, hematopathology, and solid tumor research, among others. For more information on the workshops, posters and products, we invite you to stop by at Thermo Fisher’s booth (#1308) at AMP or visit: https://www.thermofisher.com/amp.